[{"id":"cf18a12e-1232-491b-b405-b70c744952f4","acronym":"E7389-J081-114","url":"https://clinicaltrials.gov/study/NCT03207672","created_at":"2021-01-17T17:21:15.414Z","updated_at":"2024-07-02T16:35:16.765Z","phase":"Phase 1","brief_title":"Study of E7389 Liposomal Formulation in Participants With Solid Tumor","source_id_and_acronym":"NCT03207672 - E7389-J081-114","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • eribulin liposomal (E7389-LF)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 07/19/2018","primary_completion_date":" 07/19/2018","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-03-01"}]